Overview

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Treatments:
Bupropion
Nicotine